$0.009

Are you using our Portfolio Manager?

Manage your stocks with our free tool.

Get Started

General Information

Alchemia Limited
ACL
http://www.alchemia.com.au
Biotechnology
3
325

Current Price Data+

Current Price $0.009
Open $0.009
High $0.009
Low $0.009
Last Close $0.009
Volume 246480
Price Movement - ( No change )
  • +Security prices are delayed by at least 20 minutes and are indicative only.

Company Overview

Business Description

Alchemia Limited (ACL) is a biotechnology company which develops new human therapeutics based on its proprietary drug discovery and expands drug targeting and synthesis technologies in Australia and USA.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016 A -3.2 -1.0 0.0% 0.0 0.0 0.0% 0.0%
2015 A -1.6 -0.5 0.0% 0.0 0.0 0.0% 0.0%
2014 A -6.9 -2.1 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Alchemia (ACL) $3M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL (CSL) $57,431M -0.1719 0.2302 0.3448 40.8881 33.2363 24.7140 1.34% 1.39% 1.91%
Mesoblast (MSB) $842M 0.0000 0.0000 0.0000 8.9940 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $386M 0.1852 0.1031 0.0742 13.4206 12.1662 11.3260 5.18% 5.76% 6.18%
Sirtex Medical (SRX) $943M 0.3228 -0.0348 0.1291 17.7223 18.3616 16.2619 1.84% 1.81% 1.92%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.07 0.00
Market 1.07 17.50 1.46 1.66
Sector 0.74 13.50 3.07 1.25

Directors

Name Position Start Date
Mr Simon Gennari Non-Executive Chairman, Non-Executive Director 26 Feb 2016
Mr David Lamm Non-Executive Director 7 Mar 2016
Mr Darren Rael Book Non-Executive Director 12 Dec 2016

Management

Name Position
Melanie Jaye Leydin Chief Financial Officer,Company Secretary

Substantial Shareholders

Holding Name
39,426,777 (12.14%) Shomron Pty Ltd
30,800,000 (9.48%) Aust Executor Trustees Ltd

Calendar of Events

Date Event
20 February 2018 Report (Interim)
29 August 2017 Report (Prelim)
29 August 2017 Report (Annual)

© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only. DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.